LOXO > data/scans slide deck... Clinical safety and activity from a Phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions https://ir.loxooncology.com/docs/presentations/EORTC_LOXO101.pdf